Aaron G.L. Fletcher, Ph.D.
Aaron G.L. Fletcher, Ph.D. Read More »
Search Results for: p
Cookie Policy
COOKIE POLICY Cookies are small text files that are placed on your device by websites that you visit. They are used to make websites work, or work more efficiently, as well as to provide information to the owners of the website. Our website uses strictly necessary cookies, functional cookies and tracking and performance cookies. Strictly
PIPELINE
PIPELINE CLINICAL TRIALS If you or a loved one are living with cancer, and you’re interested in learning about our clinical trials we currently have open, click below to learn more. < SEE OUR TRIALS >
Actuate Homepage
THE PASSION TO PURSUE MORE Who we are Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting
Privacy Notice
PRIVACY NOTICE Last updated and effective as of December 20, 2023. This Privacy Notice explains the practices that Actuate Therapeutics, Inc. (“Actuate”, “we”, “us”, “our”) follows in connection with the personal data that we collect through this website, when you contact us directly and through our research. We may change this Privacy Notice at any
ACTUATE THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF ELRAGLUSIB PLUS RETIFANLIMAB AS INVESTIGATIONAL FIRST LINE THERAPY FOR PATIENTS WITH ADVANCED PANCREATIC CANCER
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF A MULTICENTER RANDOMIZED TRIAL OF ELRAGLUSIB PLUS FOLFIRINOX AS FIRST LINE THERAPY FOR ADVANCED PANCREATIC CANCER
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate